Regeneron Pharmaceuticals will participate in three major healthcare investor conferences in late 2026: the Jefferies Global Healthcare Conference in London on November 17, the Evercore Healthcare Conference on December 1, and Citi’s Global Healthcare Conference on December 2. These presentations will be webcast live and archived on Regeneron's investor website. This engagement highlights Regeneron's ongoing efforts to communicate its scientific advancements and business progress to investors. The company continues to lead in biotechnology with a strong pipeline and recent financial growth.
Regeneron Pharmaceuticals shares surged 13.27% to USD 927.38 on Pluang as of Nov 03, 2026 04:11 WIB, nearing its 52-week high of USD 927.89. The company’s active participation in three major healthcare investor conferences later this year may be contributing to investor interest. Despite strong gains, Pluang order activity shows a predominance of selling at 80%, with buyers at 20%.
Regeneron's shares surged 13.55% following a strong third-quarter earnings report that beat revenue and earnings expectations. This rise positively impacted health care ETFs like XLV, IBB, and XBI, which hold Regeneron shares, contributing to their g...
Regeneron Pharmaceuticals' stock surged 12% after reporting a 36% revenue increase to $5.1 billion in Q3 2026, beating analyst expectations. The boost was largely due to its partnership with Sanofi, with Dupixent sales rising 35%, and record sales of...
Regeneron reported a 36% revenue increase to $5.1 billion in Q3 2026, with record sales for Dupixent, EYLEA HD, and Libtayo. GAAP EPS rose 35% to $18.45, and non-GAAP EPS jumped 70% to $20.07. The company expanded its collaboration with Sanofi, secur...
